/

TPST

Tempest Therapeutics, Inc.Pre-market

0.6813−0.06 −8.27%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

0.7333

Prev close

0.7427

Day range

0.68130.7465

52-week range

0.681312.23

Volume

221.68K0.08×

Mkt cap

11.51M

P/E ttm

—

Fwd P/E

-0.56

EPS ttm

-3.93

Div yield

0.00%

Earnings

—

From 52w high

−94.43%

Price Chart

Yahoo Finance · delayed

TPSTOct 13, 2026O 0.7470H 0.7470L 0.6800C 0.6810−0.0620 (−8.34%)Vol 228.70K

SMA 500.9446
SMA 2001.6528

1Y change −94.09% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TPST Tempest Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −13.58%
1 month: −16.13%
3 months: −30.58%
6 months: −69.73%
Year to date: −76.27%
1 year: −94.09%

Valuation & ownership

Market cap: 11.51M
Enterprise value: 17.67M
P/E (ttm): —
Forward P/E: -0.56
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: -0.82
EPS (ttm): -3.93
EPS (forward): -1.21
Beta (5y monthly): -1.71
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 16.89M
Float: 11.08M
Short % of float: 7.25%
Short ratio (days): 0.09
Held by insiders: 30.07%
Held by institutions: 27.98%
Avg volume (3m): 2.63M
50-day average: 0.9485
200-day average: 1.66
52-week change: −94.09%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 37.4
vs 50-day SMA: −27.91%
vs 200-day SMA: −58.80%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 13.26%
Realised vol (20d, ann.): 247.2%
From 52-week high: −94.43%
From 52-week low: +0.15%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

7.00

+927.45% implied

Low 7.00Median 7.00High 7.00

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Recent actionsAll (UPDN) →

Sep 24HC Wainwright & Co. maintained · Buy

DES

About Tempest Therapeutics, Inc.

Yahoo Finance profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 4
Headquarters: Brisbane, CA, United States
Website: tempesttx.com
Officers: Dr. Matthew Angel Ph.D. President, CEO & Director
Ms. Constance Ames CPA CFO, Principal Financial & Accounting Officer, Treasurer, and Corporate Secretary
Dr. Andrew Fang Ph.D. Head of Business Development

SEAS

Seasonality · TPST

2012–2026 · monthly returns

Strongest month Oct +94.49%Weakest month Jun −11.33%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.2	-16.2	-28.1	21.3	-23.1	-27.5	-22.9	27.3	-23.5	-18.3			−76.3%
2025	9.6	-11.6	-8.8	-25.9	-16.3	14.3	6.3	37.2	3.6	-1.0	-68.6	-10.3	−73.6%
2024	-13.9	-2.1	5.4	-11.3	-4.3	-34.0	-18.7	-27.5	8.5	-34.6	3.8	-12.1	−81.0%
2023	73.0	-11.6	31.8	-8.6	-27.8	-17.0	-23.6	-44.5	-43.3	1244.3	-14.3	25.2	+282.6%
2022	-24.8	-17.9	3.7	6.8	-20.2	-25.3	-5.6	6.4	-19.4	6.3	-13.6	-28.0	−78.2%
2021	-7.9	4.6	-41.7	-4.2	3.5	-37.4	34.3	-4.1	0.4	-19.0	-15.5	-46.7	−83.6%
2020	17.8	-3.1	-31.3	-68.4	59.3	-33.8	-1.7	4.6	-9.9	-11.7	28.5	15.7	−68.2%
2019	31.8	11.8	28.0	3.6	2.8	-27.7	-15.1	-38.2	17.3	1.4	5.5	-11.4	−15.2%
2018	-25.7	-8.7	-14.6	8.5	3.5	-0.4	-0.8	-14.0	-5.7	-2.7	2.8	-27.4	−62.1%
2017	3.3	-6.3	26.4	-19.3	-15.2	21.9	-2.6	-7.9	1.4	7.0	-2.0	-6.0	−8.5%
2016	-42.2	-1.8	71.0	-11.7	-11.8	-29.5	-3.3	20.8	17.6	-29.6	-33.5	-54.3	−84.3%
2015	-1.7	4.7	-23.7	-28.8	37.1	-14.7	-1.5	-31.8	-56.3	52.8	-27.3	3.6	−77.9%
2014	2.4	15.3	-17.1	-9.2	-10.7	26.5	7.0	37.7	22.9	17.7	29.3	75.1	+383.8%
2013	7.5	19.4	-16.3	30.0	6.7	10.0	-7.6	-9.2	-14.0	-2.4	-1.0	-4.5	+9.2%
2012												-7.5	−7.5%

INSD

Insider Activity · TPST

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Mar 23, 2026	Angel MatthewChief Executive Officer	Purchase at price 1.75 per share.	231.5K	$405.09K

TPST

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TPST

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Tempest Therapeutics, Inc.

Seasonality · TPST

Insider Activity · TPST

Congress Trades · TPST

Investors Holding TPST

Insider Activity · TPST

Seasonality · TPST

Congress Trades · TPST

Investors Holding TPST

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Tempest Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News